Introduction
Autoimmune pancreatitis is rare and appears in two different clinical entities, which are mainly differentiated by histological features. Type 1 autoimmune pancreatitis belongs to the immunoglobulin G4 (IgG4)-related diseases which are immune-mediated and share clinical, pathological and serological features. These include the tumor-like enlargement of the involved organs, an inflammatory infiltration by lymphoplasmacytic cells with a predominance of IgG4-positive plasma cells, venulitis, extended sclerosis and fibrosis [1] . Elevated serum levels of IgG4 are present in 60-70% of patients with IgG4-related disease [2] . Predominantly male patients in the sixth decade are affected by this type of autoimmune pancreatitis. Treatment with glucocorticoids is most often effective and the clinical response to this treatment is a diagnostic criterion [3] . Beside pancreas involvement the following conditions may be part of this systemic disease: extrahepatic bile duct stricture, sclerosing sialadenitis, orbital disease with enlargement of the lacrimal gland or orbital pseudotumors and retroperitoneal fibrosis.
In contrast, type 2 autoimmune pancreatitis does not belong to the IgG4-related diseases, affects younger patients in the fourth decade and is evenly distributed between genders. The histological features may include lymphoplasmacytic infiltrates, but these are mostly negative for IgG4 immunohistological staining. The characteristic histological feature is the infiltration by neutrophil granulocytes, sometimes being so dense to appear as microabscesses in ducts and lobuli. The granulocytic infiltration frequently involves and destroys the epithelium of the pancreatic ducts, thus called granulocyte epithelial lesions.
Both types of autoimmune pancreatitis may present with obstructive jaundice and the onset of a diabetic condition. The clinical picture of pain and elevation of serum amylase is rare. Here we report the case of a male patient with type 1 autoimmune pancreatitis with classical symptoms of pancreatic cancer, emphasizing the difficulties of the diagnostic process in such cases.
Case Report
A 67-year-old male patient presented with painless jaundice, dark-brown urine and acholic stools. The general practitioner had diagnosed onset of a diabetic condition with a HbA1c of 8.5% and a weight loss of 4 kg, corresponding to a weight loss of 5%. His antecedent history showed prostate cancer treated by prostatectomy 6 years before and a malignant melanoma on his back 5 years before. Both malignant conditions were followed periodically and did not show any signs of recurrence. Furthermore the patient had had borreliosis 30 years earlier and polymyalgia rheumatica for 2 years. The latter had been treated with low-dose steroids for one and a half years. During the first 6 months, 5 mg of prednisone was given daily, then prednisone was tapered to 2.5 mg twice a week.
A CT scan showed a double duct sign without clear delineated tumor, no calcification of the pancreas nor infiltration of the vessels ( fig. 1 ). A sonography was performed, which showed a mass of 15 × 23 mm in the pancreatic head. Blood tests showed normal values of the tumor markers CEA (2.4 μg/l) and CA19-9 (<3 kU/l) as well as total bilirubin of 50 µmol/l. Surgery was indicated since we suspected pancreatic cancer due to the clinical and radiological findings.
Infiltration of the mesocolic artery found during surgery made the planned Whipple procedure impossible. Biopsies were taken from the pancreatic head. A cholecystectomy and a biliodigestive anastomosis were performed. The histological results showed chronic inflammation with fibrosis and fat necrosis, but no signs of malignancy. After discussion of the case on a multidisciplinary tumor board, a secondary percutaneous biopsy was taken. This one showed chronic periductal inflammation with infiltration of plasma cells, sclerosis, venulitis, parenchymal atrophy ( fig. 2, fig. 3a ) and strong positive immunohistochemical staining for IgG4 ( fig. 3a, b) . This led to the diagnosis of type 1 autoimmune pancreatitis in the absence of granulocytic epithelial lesions.
We determined IgG4 in the serum, which was elevated (3.4 g/l, normal range 0.03-2.01 g/l), although the other autoimmune rates (rheumatoid factors, antinuclear antibodies, c-ANCA, p-ANCA) were normal. A follow-up CT scan 6 weeks later showed a 15% reduction in the craniocaudal dimension, resulting in a less prominent pancreas with inhomogeneous alteration of the structure. Nevertheless, neither calcification nor tumor mass was found ( fig. 4 ). As the patient was meanwhile asymptomatic, further steroid therapy was omitted.
Discussion
Sarles et al. [4] first suspected autoimmune pancreatitis in 1961 when they found an idiopathic chronic pancreatitis with hypergammaglobulinemia in a patient. Meanwhile two types of autoimmune pancreatitis have been described. Type 1 autoimmune pancreatitis is also referred to as IgG4-related disease [5] .
Type 1 autoimmune pancreatitis occurs in the sixth decade in 80% of cases and is more common among men [3] . The clinical findings match those found in our patient (jaundice, new-onset diabetes, weight loss) and diffuse pancreatic enlargement with diffusely irregular pancreatic duct ('sausage-shaped pancreas') in the abdominal CT scan [2, 3] . The histological pattern found in the second biopsy was typical, showing lymphoplasmacytic sclerosing pancreatitis with periductal lymphoplasmacytic infiltrate, fibrosis, venulitis and an abundance of IgG4-positive plasma cells. Typically granulocytic epithelial lesions are absent [3, 6] . The serum IgG4 level is elevated, and other organs may be involved (e.g. sialadenitis, cholangitis, retroperitoneal fibrosis, tubulointerstitial nephritis) [3] .
The diagnosis of autoimmune pancreatitis is challenging due to its rare occurrence and its clinical similarity to pancreatic cancer. Several groups have published criteria to allow its diagnosis [7] . A Japanese Group used pancreatic imaging (diffuse or segmental narrowing of the main pancreatic duct with irregular wall and diffuse or localized enlargement of the pancreas), laboratory data (high serum γ-globulin and/or IgG, or the presence of autoantibodies, such as antinuclear antibodies and rheumatoid factor), histopathological findings of the pancreatic biopsy, endocrine and exocrine function of the pancreas, and the presence of other associated autoimmune disorders (sclerosing cholangitis, sclerosing sialadenitis or retroperitoneal fibrosis) [8] . A Korean group used pancreatic imaging (diffuse enlargement/ swelling of the pancreas), laboratory findings (elevated levels of IgG or detected autoantibodies), histopathological findings of the pancreatic biopsy and the response to steroid therapy [9] . The Mayo Clinic defined 'HISORt' for histology, imaging, serology, other organ involvement and response to corticosteroid therapy) [2] . The Verona group added to the mentioned criteria the association with autoimmune diseases (e.g. ulcerative colitis, Crohn's disease, Sjögren's syndrome, autoimmune thyroiditis) [10] .
The diagnostic criteria are overlapping with those of pancreatic cancer; the clinical symptoms are typical of pancreatic cancer and may also mimic gallbladder cancer (jaundice, right upper abdominal discomfort, nausea, fatigue) [11] . The findings on imaging studies may be challenging because a pancreatic mass may show instead of the typical diffusely irregular pancreatic duct within a diffusely enlarged gland with diffuse rim enhancement [1] . Elevated IgG4 levels were thought to be a specific diagnostic tool for autoimmune pancreatitis, but some patients are seronegative and about 10% of patients are positive without having autoimmune pancreatitis, but with pancreatic cancer or cholangiocarcinoma [12, 13] . On the other hand, the tumor marker CA19-9 was considered to be specific for pancreatic cancer, but in 47-73% of cases with autoimmune pancreatitis CA19-9 is elevated [7, 14] . Therefore no single diagnostic test is sensitive and specific enough for autoimmune pancreatitis; rather, all the criteria have to be evaluated together combined with the clinical answer to treatment.
The treatment of choice for autoimmune pancreatitis are steroids. After an initial higher dose for 2-4 weeks, the acute symptoms of jaundice regress, and the steroids may be re- 
